Stockscreener 앱 받기
2.45
7.93%
0.18
시간 외 거래:
2.34
-0.11
-4.49%
전일 마감가:
$2.27
열려 있는:
$2.26
하루 거래량:
245.08K
Relative Volume:
0.94
시가총액:
$85.51M
수익:
$3.25M
순이익/손실:
$-116.80M
주가수익비율:
-0.9108
EPS:
-2.69
순현금흐름:
$-98.17M
1주 성능:
+22.50%
1개월 성능:
+22.50%
6개월 성능:
-70.59%
1년 성능:
-84.19%
1일 변동 폭
$2.18
$2.45
1주일 범위
$1.98
$2.50
52주 변동 폭
$1.64
$27.35
Rapt Therapeutics Inc Stock (RAPT) Company Profile
명칭
Rapt Therapeutics Inc
전화
(650) 489-9000
주소
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-14 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-05-10 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-05-10 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-02-22 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-02-21 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-02-21 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-02-21 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-02-20 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2024-02-16 | 개시 | Evercore ISI | Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-09-14 | 개시 | Berenberg | Buy |
| 2023-08-09 | 개시 | Stifel | Buy |
| 2023-06-15 | 개시 | Barclays | Overweight |
| 2023-01-04 | 개시 | Guggenheim | Buy |
| 2022-12-01 | 개시 | Goldman | Buy |
| 2022-09-21 | 개시 | CapitalOne | Overweight |
| 2022-05-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-12-09 | 개시 | JP Morgan | Overweight |
| 2021-08-12 | 개시 | SVB Leerink | Outperform |
| 2021-06-21 | 개시 | Piper Sandler | Overweight |
| 2020-06-01 | 개시 | H.C. Wainwright | Buy |
| 2020-05-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-04-13 | 개시 | ROTH Capital | Buy |
| 2019-11-25 | 개시 | BMO Capital Markets | Outperform |
| 2019-11-25 | 개시 | UBS | Buy |
| 2019-11-25 | 개시 | Wells Fargo | Outperform |
모두보기
Rapt Therapeutics Inc 주식(RAPT)의 최신 뉴스
Vanguard Group Inc's Strategic Acquisition in RAPT Therapeutics Inc - GuruFocus.com
RAPT Therapeutics stock plunges to 52-week low of $1.65 By Investing.com - Investing.com Australia
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Average Rating of "Hold" by Analysts - MarketBeat
RAPT Therapeutics stock plunges to 52-week low of $1.65 - Investing.com
RAPT stock touches 52-week low at $1.72 amid sharp yearly decline - Investing.com
Point72 Asset Management L.P. Acquires 706,900 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - MarketBeat
RAPT Therapeutics Inc (RAPT) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Cubist Systematic Strategies LLC Increases Stake in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - MarketBeat
XTX Topco Ltd Invests $108,000 in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
RAPT Therapeutics' SWOT analysis: biotech stock faces clinical hurdles - Investing.com
RAPT Therapeutics, Inc. (RAPT): Worst 52-Week Low Stock to Buy Now - Yahoo Finance
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
RAPT Therapeutics, Inc. (RAPT) Stock Falls Following FDA Setback; Short Sellers Cite Unprofitability - Insider Monkey
15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers - Insider Monkey
RAPT stock touches 52-week low at $1.76 amid sharp annual decline - Investing.com India
Daily Progress: RAPT Therapeutics Inc (RAPT) Drop -7.25, Closing at 1.79 - The Dwinnex
Federated Hermes Inc. Boosts Stock Holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - MarketBeat
Acadian Asset Management LLC Raises Stake in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - MarketBeat
RAPT Therapeutics (NASDAQ:RAPT) Price Target Cut to $2.00 by Analysts at UBS Group - Defense World
Market Highlights: RAPT Therapeutics Inc (RAPT) Ends on a High Note at 2.01 - The Dwinnex
RAPT Therapeutics (NASDAQ:RAPT) Given New $2.00 Price Target at UBS Group - MarketBeat
RAPT Therapeutics stock hits 52-week low at $1.82 - Investing.com India
In the Green: RAPT Therapeutics Inc (RAPT) Closes at 2.06, Up/Down -5.30 from Previous Day - The Dwinnex
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
RAPT Therapeutics stock hits 52-week low at $2.11 By Investing.com - Investing.com Canada
Q3 2024 EPS Estimates for RAPT Therapeutics, Inc. Increased by HC Wainwright (NASDAQ:RAPT) - MarketBeat
HC Wainwright Comments on RAPT Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:RAPT) - Defense World
HC Wainwright Reiterates "Neutral" Rating for RAPT Therapeutics (NASDAQ:RAPT) - MarketBeat
Rapt Therapeutics stock steady as H.C. Wainwright assesses financials and risks - Investing.com Canada
HC Wainwright Reaffirms Neutral Rating for RAPT Therapeutics (NASDAQ:RAPT) - Defense World
RAPT Therapeutics stock plunges to 52-week low of $2.13 - Investing.com
Financial Fitness Check: Examining RAPT Therapeutics Inc (RAPT)’s Key Ratios - The Dwinnex
Vanguard Group Inc. Has $22.39 Million Stock Position in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - MarketBeat
Vanguard Group Inc. Raises Stock Holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
Reviewing RAPT Therapeutics (NASDAQ:RAPT) & Enliven Therapeutics (NASDAQ:ELVN) - Defense World
RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q2 2024 - MSN
RAPT Therapeutics Reports Second Quarter 2024 Financial Results - GlobeNewswire
RAPT stock touches 52-week low at $2.6 amid sharp annual decline - Investing.com
Analysts Set RAPT Therapeutics, Inc. (NASDAQ:RAPT) PT at $24.67 - MarketBeat
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Average Rating of “Hold” by Brokerages - Defense World
Price T Rowe Associates Inc. MD Sells 1,385,386 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
Acadian Asset Management LLC Makes New Investment in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
Viking (VKTX) Q2 Earnings Beat, Stock Up on Pipeline Updates - Zacks Investment Research
RAPT Therapeutics Inc (RAPT) Stock: A Year of Stock Market Dynamics - The InvestChronicle
RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus - Seeking Alpha
Biopharma layoff tracker 2024: Merck, Rapt, Aslan and more cut staff - PharmaLive
RAPT Therapeutics (NASDAQ:RAPT) Given "Neutral" Rating at HC Wainwright - MarketBeat
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans - MSN
Taysha Gene Therapies (NASDAQ:TSHA) Earns “Buy” Rating from Needham & Company LLC - Defense World
Trial stumble leads to major downsizing at RAPT Therapeutics - The Pharma Letter
Finance Watch: A Year After Investors Denied Infinity Merger, MEI Considers Strategic Alternatives - Scrip
Rapt Therapeutics Inc (RAPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.47%
자본화:
|
볼륨(24시간):